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Result: We showed that in the presence
of PSP, c-T3 treatment induce a drastic
activation of AMP-activated protein kinase
(AMPK). This was accompanied with
inactivation of acetyl-CoA carboxylase
(ACC), as evidenced by the increased
phosphorylation levels at Ser 79. In addi-
tion, PSP treatment also sensitized cancer
cells toward c-T3-induced cytotoxicity.
Furthermore, we demonstrated for the first
time that combination of PSP and c-T3
treaments significantly reduced the growth
of prostate tumor in vivo.
Conclusion: Our results indicate that PSP
and c-T3 treaments may have synergistic
anti-cancer effect in vitro and in vivo,
which warrants further investigation as a
potential combination therapy for the
treatment of cancer.
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Objective: Kallikrein-related peptidase 4
(KLK4) is a protease with elevated produc-
tion in prostate cancer versus benign tis-
sue. KLK4 expression is associated with
prostate cancer risk, and its activity
favours tumour progression through
increasing cell motility and growth.
Importantly, over-production of KLK4 in
prostate glandular cells precedes tumour
formation, positioning the enzyme to play
a role in early remodelling of the tumour
microenvironment, a process essential for
tumour growth. We sought to identify the
proteins and downstream signalling path-
ways targeted by KLK4 activity, to define
its role in tumour microenvironment
remodelling and evaluate the efficacy of
KLK4 inhibition as a cancer therapy.
Methods: KLK4-induced gene expression
changes in prostate myofibroblasts, abun-
dant cells in the tumour microenviron-
ment, were assessed by microarray.
Complementary proteomic approaches
were employed for high-depth identifica-
tion of KLK4 targets in cell secretions.
Ingenuity Pathway Analysis software and
in vitro validation was used to determine
the resulting effect on cell function.
Results: KLK4 induced extensive gene
expression changes in prostate myofibro-
blasts, through activation of transforming
growth factor beta 1 (TGFb1) and prote-
ase activated receptor-1 (PAR-1) signal-
ling. Forty-five novel KLK4 substrates
were also identified, some of which regu-
late the activity of TGFb1, a key factor in
tumour microenvironment remodelling.
KLK4 has before been shown to activate
PAR-1 on prostate myofibroblasts, and
herein we showed this to induce expres-
sion of fibroblast growth factor-1 and -5.
Conclusions: KLK4 appears to initiate
microenvironment remodelling via proteo-
lytic activation of TGFb1 and PAR-1 sig-
nalling. KLK4 is a promising target for
inhibition as cancer therapy.
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Objective: In castrate-resistant prostate
cancer (CRPC), the prevailing organ for
metastasis is bone, where the survival of
cancer cells is regulated by the permissive
metastatic niche offered by the bone mar-
row. The tumour microenvironment and
cellular interactions with the matrix and
bone cells enable metastasis and lead to
cancer cells becoming androgen resistant.
Hence, 3D models that mimic CRPC in
terms of an androgen deprivation state
(ADS) are needed to identify the mecha-
nisms for CPRC growth in bone and fur-
ther develop therapeutic strategies.
Methods: A humanised 3D bone model
was engineered from melt electrospun
fibres and seeded with patient-derived
osteoblastic cells. The construct was osteo-
genically differentiated over 8 weeks in
culture. Prostate cancer cells, such as
LNCaP, C4-2B and PC3 were seeded
(3 9 105/cm2) on the construct and co-
cultured in FBS or CSS – representative of
ADS in vivo.
Results: The bone construct exhibited a
dense extracellular matrix (SEM, immuno-
histochemistry). Constructs were viable up
to 21 days and a mixed population com-
posed of osteoblasts and osteocytes was
observed. When seeded on the bone con-
structs, cancer cells were shown to colonise
the neo-bone matrix with LNCaP cells cul-
tured in CSS displaying a more mesenchy-
mal morphology. The expression of
alkaline phosphatase in media was signifi-
cantly altered from day 7 to day 21 and
differences in the expression of bone and
cancer genes were observed by qRT-PCR.
Conclusions: This model has proven to
replicate CRPC in vitro and will be useful
to assess the relevance of standard treat-
ments and unravel new treatment
approaches for CRPC.
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Background: Chromosomal translocations
between distinct gene loci are now recog-
nized as a molecular hallmark of prostate
cancer. More than 50% of all primary pros-
tate cancers harbour an androgen induced
TMPRSS2-ERG gene fusion. Recently, it
has been noted that advanced prostate can-
cers have genomic re-arrangements that
disrupt the DNA mismatch repair gene
MSH2. To date it is unknown whether
translocations in MSH2 occur via the same
mechanism as TMPRSS2 and if they are
androgen induced.
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